Welcome to our dedicated page for Accuray news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray stock.
Accuray Incorporated develops, sells, and supports radiation therapy systems used in cancer treatment and neuro-radiosurgery. Company news centers on product and service revenue, installation timing, gross margin factors, and non-GAAP operating measures, as well as updates tied to its CyberKnife and Radixact treatment platforms and the Accuray Stellar configuration.
Recurring developments also include commercial leadership changes, equity inducement awards, and strategic transformation actions involving organizational realignment, cost structure, outsourcing, engineering resources, and sales enablement. Accuray's updates frame the company as a medical technology issuer with capital equipment sales, service revenue, and global commercialization priorities.
Accuray Incorporated (NASDAQ: ARAY) is set to release its financial results for the second quarter of fiscal year 2023, which ended on December 31, 2022. This announcement will occur after the market closes on February 1, 2023. Following the results, management will conduct a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the figures. Participants can join via provided dial-in numbers or listen in through a live webcast available on the Investor Relations section of their website.
Accuray (NASDAQ: ARAY) announced that Auckland Radiation Oncology (ARO) has become the first center in New Zealand to use the advanced CyberKnife S7™ System for precise cancer treatments. This system allows for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) with high accuracy, often requiring only 1 to 5 outpatient sessions. The CyberKnife System enhances treatment efficiency, enabling ARO to treat more patients daily. CEO Suzanne Winter emphasized that this innovation broadens access to effective cancer care, while ARO’s Clinical Director Dr. Benji Benjamin noted the system’s potential to greatly improve treatment precision and minimize side effects.
Accuray Incorporated (NASDAQ: ARAY) will participate in the B. Riley Securities' 3rd Annual Oncology Conference on January 18-19, 2023. A virtual Fireside Chat is scheduled for January 18 at 7:00am PST/10:00am EST. The conference showcases over 30 healthcare companies and features discussions on innovative therapies and technologies in oncology. Attendees can access a live webcast on the Accuray website, with a replay available afterward. Accuray is dedicated to advancing radiation therapy solutions for cancer treatment.
Accuray Incorporated (NASDAQ: ARAY) reported its recognition for superior service in radiation oncology in the IMV ServiceTrak™ Radiation Oncology 2022 report, achieving the highest overall service performance scores in the industry. The company excelled in customer satisfaction, particularly in fields like service follow-up and field engineer competence. Customers praised Accuray's commitment to support and innovation. This marks the third consecutive year of increased customer repurchase intent for Accuray's radiation delivery systems, reflecting their dedication to quality and technological advancement.
Accuray (NASDAQ: ARAY) announced the installation of its second Radixact® System at the Oscar Lambret Center in Lille, France, enhancing cancer treatment capabilities. This system integrates ClearRT™ kVCT Imaging and Synchrony® technologies, improving treatment precision and versatility for various cancers. The Oscar Lambret Center, part of Unicancer, has a long history of utilizing Accuray technology. This partnership aims to deliver personalized, high-quality care, adapting to patient needs and medical conditions, ultimately increasing community treatment access.
Accuray Incorporated (NASDAQ: ARAY) reported Q1 fiscal 2023 results with net revenue of $96.5 million, down 10% year-over-year, affected by supply chain constraints and a $5.8 million foreign exchange hit. Gross orders were flat at $69.8 million, with a 6.5% increase on a constant currency basis. The GAAP net loss widened to $5.4 million, compared to a loss of $1.0 million last year. Adjusted EBITDA decreased to $1.9 million from $5.4 million. The company maintains its full-year guidance, highlighting strong demand for its precision radiation therapy solutions amidst ongoing challenges.
Accuray (NASDAQ: ARAY) has submitted the registration dossier for its Tomo® C radiation therapy system to China's National Medical Products Administration (NMPA). This milestone, shared during the Q4 FY2022 earnings call, aims to enhance access to radiation treatment for cancer patients in China. The Tomo C system is noteworthy as it is the first joint venture product made in China and addresses the growing demand for effective cancer therapies, with new cases projected to rise by 50% by 2040. Suzanne Winter, CEO, highlighted the expected growth in the Type B market, reinforcing Accuray's competitive edge.
Accuray Incorporated (NASDAQ: ARAY) announced that the CyberKnife® System has received reimbursement approval from Japan's Ministry of Health, Labor and Welfare for treating trigeminal neuralgia (TN). TN is a painful condition affecting the trigeminal nerve, impacting daily life significantly. The approval enables patients in Japan to access this innovative treatment, which offers a precision alternative to traditional methods. The CyberKnife System's unique technology allows for accurate radiation delivery in a single outpatient procedure, enhancing treatment options for the approximately 5,000 people affected by TN in Japan.
GE Healthcare and Accuray Incorporated (NASDAQ: ARAY) have signed a global commercial collaboration agreement aimed at enhancing personalized cancer treatment. The partnership will merge GE's advanced diagnostic tools with Accuray's radiation therapy technologies to improve patient care throughout the cancer journey, focusing initially on lung and brain cancers. This collaboration promotes early detection and precise treatment delivery, while also emphasizing digitalization and interoperability in healthcare systems. The companies aim to increase access to effective radiation therapy for cancer patients globally.
Accuray Incorporated (NASDAQ: ARAY) will announce its financial results for the first quarter of fiscal year 2023, which concludes on September 30, 2022, after market close on November 2, 2022. Following the release, management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The call can be accessed via dial-in numbers or through a live webcast on their Investor Relations website.
Accuray is focused on innovative radiation therapy solutions for oncology and neuro-radiosurgery, aiming to enhance patient outcomes.